Pandion Therapeutics (PAND) Stock Price, News & Analysis

Company Overview

Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, develops various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprising an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a tethered bifunctional molecule that utilizes its IL-2 mutein effector module coupled with a MAdCAM-tether module to deliver the IL-2 mutein effector to the gastrointestinal tract where MAdCAM is expressed. It has a license and collaboration agreement with Astellas Pharma Inc. to discover and develop novel compounds for autoimmune diseases of the pancreas, including type 1 diabetes. The company was formerly known as Immunotolerance, Inc. and changed its name to Pandion Therapeutics, Inc. in June 2017. Pandion Therapeutics, Inc. was incorporated in 2016 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $60.05 to $60.05
• 50-Day Range: $59.90 to $60.28
• 52-Week Range: $10.28 to $62.90
• Volume: N/A
• Average Volume: 355,921 shs
• Market Capitalization: $1.77 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PAND Stock Analysis - Frequently Asked Questions

How were Pandion Therapeutics' earnings last quarter?

Pandion Therapeutics, Inc. (NASDAQ:PAND) issued its earnings results on Monday, November, 16th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.07. The business had revenue of $2.63 million for the quarter, compared to the consensus estimate of $1 million.

When did Pandion Therapeutics IPO?

Pandion Therapeutics (PAND) raised $94 million in an IPO on Friday, July 17th 2020. The company issued 5,500,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO.

What other stocks do shareholders of Pandion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pandion Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Moderna (MRNA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Curaleaf (CURLF) and Dynavax Technologies (DVAX).

Company Calendar

• Last Earnings: 11/16/2020
• Today: 10/10/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PAND
• CUSIP: N/A
• CIK: N/A
• Web: www.pandiontx.com
• Phone: 617-393-5925
• Fax: N/A
• Employees: 56
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $970,000.00
• Price / Sales: 1,827.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 29,516,000
• Free Float: N/A
• Market Cap: $1.77 billion
• Optionable: Not Optionable
• Beta: N/A